The pressing need for more research to inform our understanding of the science of hemophilia inhibitors has been discussed for decades. The advances made in genetic mutation analysis and genotyping have given physicians and researchers more insights into bleeding severity and the genetic risks associated with developing an inhibitor.
More recent studies on biomolecular immunology have offered additional clues into the
immunologic aspects to inhibitor development and the function of specific cells in response to FVIII.
In 2018, the National Heart, Lung and Blood Institute Branch of the National Institutes of Health hosted a State of the Science (SOS) Workshop to foster broad-based input among US and international clinicians and scientists into the development of a coordinated national blueprint for basic, translational and clinical research on factor VIII immunogenicity and FVIII inhibitor prevention and eradication.